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Abstract 
MiR-744 is a short, single-stranded non-coding 
RNA molecule. Gene encoding miR-744 locates at 
chromosome 17. Two mature forms (miR-744-5p 
and miR-744-3p) have been reported to be 
implicated in cellular process leading to the 
development of human diseases. The function of 
miR-744 is dependent on cell type and contexts. 
MiR-744 could function as tumor suppressor or 
tumor promoter and the role varies in different 
cancer types. 
Keywords 
MicroRNA-744, MicroRNA-744-5p, MicroRNA-
744-3p 
Identity 
Other names: hsa-mir-744, MIRN744, miR-744 
HGNC (Hugo): MIR744 
Location: 17p12 
Local order 
Based on Mapviewer Genes on Sequence, genes 
flanking MIRN10B oriented from centromere to 
telomere on 17p12 includes: 
DNA/RNA 
Description 
RNA Sequence:  
Pre-hsa-miR-744 (MI0005559):  
UUGGGCAAGGUGCGGGGCUAGGGCUAACA
GCAGUCUUACUGAAGGUUUCCUGGAAACC
ACGCACAUGCUGUUGCCACUAACCUCAAC
CUUACUCGGUC 
Mature miR-744-5p (MIMAT0004945):  
11-UGCGGGGCUAGGGCUAACAGCA-32 
Mature miR-744-3p (MIMAT0004946):  
68-CUGUUGCCACUAACCUCAACCU-89 
Transcription 
Primary miR-744 is transcribed by RNA polymerase 
II to generate pri-miRNA in the nucleus. Nuclear pri-
hsa-miR-744 is processed by RNase III, Drosha, 
generating stem-loop structured RNAs called pre-
hsa-miR-744. Pre-hsa-miR-744 is then exported into 
the cytoplasm. In the cytoplasm, another RNase III, 
Dicer, cleaves the pre-hsa-miR-744 and generates 2 
mature miRNAs: hsa-miR-744-5p (previously 
known as hsa-miR-744), and hsa-miR-744-3p 
(previously known as hsa-miR-744*). 
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Protein 
MicroRNAs are not translated into amino acids 
Mutations 
Mutations have not been described. 
Implicated in 
Breast cancer 
miR-744-5p was able to suppress the cancer cell 
growth by reducing proto-oncogene eukaryotic 
translation elongation factor 1A(eEF1A2) 
expression in MCF7 cells. Moreover, over-
expression of this microRNA could be induced by 
candidate anti-tumor agent resveratrol, suggesting 
that miR-744-5p could perform as a novel regulator 
involved in the resveratrol-related therapy 
(Vislovukh et al., 2013). 
Cervical carcinoma 
Expression of miR-744-5p is responsive to the 
administration of 1'S-1'-acetoxychavicol acetate 
(ACA) and cisplatin (CDDP) in cervical carcinoma 
cell line Ca Ski (low sensitivity to cisplatin) and 
HeLa (high sensitivity to cisplatin). Cervical cancer 
cell lines treated with ACA and/ or CDDP over two 
hours exhibited an enhancement on expression in 
miR-744-5p. Further, the predicted target transcripts 
are involved in signaling pathways regulating 
apoptosis and cell cycle progression (Phuah et al., 
2013). In HeLa cells transfected with siRNA against 
T-cell intracellular antigen 1 (TIA1) and TIA1 
related/like (TIAR/TIAL1), significant increase in 
miR-744-5p was observed (Sánchez-Jiménez et al., 
2013) 
Gastric cancer (GC) 
In GC, serum miR-744-5p quantity could act as early 
cancer marker. High circulating miR-744-5p level 
was found in early GC patients. Comparing the 
diagnostic efficacy with the other candidate markers, 
miR-744-5p showed the greatest area under the 
curve (AUC) value (Song et al., 2012). In a 
retrospective study using pre-diagnosis serum 
collected at different time-point before confirmation 
of GC, serum miR-744-5p level was shown to be 
elevated gradually during GC development (Song et 
al., 2012). 
Hepatocellular carcinoma (HCC) 
Under-expression of miR-744-5p was observed in 
HCC tissues compared with the normal counterparts 
(Tan et al, 2014; Lin et al., 2014). Furthermore, 
reduced miR-744-5p exhibited a significant linkage 
with HCC cases demonstrating multiple tumor nodes 
or microvascular invasion (Tan et al., 2014). In HCC 
cell lines with low endogenous miR-744-5p 
expression, introduction of miR-744 mimics reduced 
HCC growth (Lin et al., 2014). Using luciferase 
reporter assays, it was demonstrated that miR-744-
5p was able to suppress the HCC cell growth by 
targeting c-Myc (Lin et al., 2014). HCC tissues with 
low miR-744-5p had higher c-Myc protein 
expression (Lin et al., 2014). 
Prognosis 
The HCC cases with relative lower miR-744-5p 
expression level had higher recurrence rate after 
receiving liver transplantation. Mature miR-744-5p 
could serve as an independent prognostic predictor 
for the overall survival and recurrence-free survival 
in HCC patients (Tan et al., 2014). 
Head and neck cancer (HNC) 
Disease 
High expression of miR-744-5p was found in head 
and neck cancer (Nurul-Syakima et al., 2011). 
Multiple myeloma (MM) 
Reduced circulating miR-744-5p level is linked to 
MM. Compared with the healthy controls, MM 
patients exhibited a significantly lower circulating 
level of serum miR-744-5p, especially in the cases at 
advanced stage. Quantity of miR-744-5p was 
positively related with the seral level of albumin, 
hemoglobin and thrombocytes. In contrast, it was 
negatively correlated with the level of ?2-
microglobulin, creatinine and lactate dehydrogenase. 
It is suggested that miR-744-5p is involved in the 
regulation of tumor mass and tumor activity 
(Kubiczkova et al., 2014). 
Prognosis 
MM patients with relatively higher serum miR-744-
5p level had a better chance to survive than the serum 
miR-744-5p reduced group (Kubiczkova et al., 
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2014). Low miR-744-5p level was associated with 
poor overall survival and time to progression 
(Kubiczkova et al., 2014). 
Prostate adenocarcinoma 
Prolonged overexpression of miR-744-5p exerted a 
suppression on tumorigenesis in vivo, which might 
be due to chromosomal instability in prostate 
adenocarcinoma cells caused by prolonged 
activation of Ccnb1 (Huang et al., 2012).  In prostate 
adenocarcinoma cell line, miR-744-5p 
overexpression, however, was found to be able to 
promote the cancer cell growth by enhancing the 
Cyclin B1 (Ccnb1) expression. 
Chronic hepatitis B infection (CHB) 
Down-regulation of miR-744-5p was positively 
correlated with the severity of liver injury (Zhang et 
al., 2012). Serum miR-744-5p level was found to be 
a precise marker for distinguishing CHB, non-
alcohlic steatohepatitis (NASH) patients from 
healthy controls. Further, miR-744-5p level was 
correlated with liver functional parameters (Zhang et 
al., 2012). 
Chikungunya Virus (CHIKV) Infection 
In NEK293T cells (origin: human embryonic kidney 
cells) and human dermal fibroblasts infected with 
CHIKV, significant increase in miR-755-5p 
expression is observed in 12 hour (Sexena T et al., 
2013). 
Early onset pre-eclampsia (EOPE) 
In chorioamniotic membranes tissue collected from 
early onset pre-eclampsia cases, promoter of miR-
744-5p gene was found to be hypermethylated 
(Ching et al., 2014). The functions of miR-744-5p in 
pre-eclampsia remains to be elucidated. 
Breast cancer 
MiR-744-3p was found to be one of the microRNAs 
significantly down-regulated in HER2-positive 
breast cancers compared with the HER2-negative 
ones. Furthermore, overexpression of miR-744-3p 
resulted in the suppression of growth in HER2-
positive breast cancer cell line KLP-4 and 
downregulation of HER2 expression (Leivonen et 
al., 2014). 
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